Clinical trials: Severe Allergic Asthma
Allergic Bronchopulmonary Aspergillosis, Severe Asthma
Real-World Effectiveness of Benralizumab in Allergic Bronchopulmonary Aspergillosis
An open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis
- Conditions
- Allergic Bronchopulmonary Aspergillosis, Severe Asthma, ABPA
- Trial name
- NCT07530770
- Testing
- Fasenra
- Where
- 2 sites in China
- Volunteers
- 20 people
- Sponsor
- Qianfoshan Hospital
Allergic Asthma
Combination Therapy of Omalizumab and Allergen Immunotherapy for Moderate to Severe Asthma
The combined treatment of anti-IgE monoclonal antibody and standardized allergen immunotherapy has good efficacy and safety in allergic diseases.
- Trial name
- NCT06771934
- Testing
- Allergen-specific immunotherapy(AIT), omalizumab
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Qianfoshan Hospital
Allergic Asthma
The REALITY Study - a Real-life Long-term Analysis of Xolair Therapy
The primary objective is to assess the clinical effectiveness of long-term omalizumab therapy in 240 patients treated over an 8 year period in a real-life clinical setting and to compare the pre- and post-treatment clinical…
- Trial name
- The Reality (NCT01776177)
- Where
- United States
- Volunteers
- 240 people
- Sponsor
- Joseph D. Diaz, MD
Asthma
Study to Evaluate the Safety, Pharmacology and Efficacy of WIN378 in Adults With Moderate or Severe Asthma
This is a global Phase 2 study divided in two parts. Part A is a double-blind, randomized dose-range finding study in adults with moderate to severe asthma to confirm the dosing regimen of WIN378 that can be tested in future…
- Trial name
- Polaris (NCT07120503)
- Testing
- WIN378
- Where
- 73 sites in United States, Argentina and 6 more
- Volunteers
- 600 people
- Sponsor
- Windward Bio
Severe Allergic Asthma
Nocturnal TLA for Severe Allergic Asthma After Withdrawal of Omalizumab Therapy
This is a randomized, controlled study with a 48-week treatment phase to determine the clinical efficacy of temperature controlled laminar flow device (TLA, Airsonett™) in the patients with severe allergic asthma who are…
- Trial name
- NCT03480815
- Testing
- Nocturnal Temperature Controlled Laminar Flow Device, None Device
- Where
- Taiwan
- Volunteers
- 24 people
- Sponsor
- Chang Gung Memorial Hospital
Rhinoconjunctivitis
Evaluation of Safety and Efficacy of Specific Immunotherapy With Recombinant Major Allergens of Timothy Grass Pollen Adsorbed Onto Aluminium-hydroxide in Patients With IgE-mediated Allergic Rhinoconjunctivitis +/- Controlled Asthma
Efficacy and Safety from a high-dosed subcutaneous recombinant preparation
- Trial name
- AMETHYST (NCT00671268)
- Testing
- AL0704rP
- Where
- Germany
- Volunteers
- 256 people
- Sponsor
- Allergopharma GmbH & Co. KG
Chronic Rhinosinusitis With Nasal Polyps
Real Life Study of Biologicals in Patients With Severe CRSwNP
This study is a pragmatic, real-life, observational study recruiting adult patients with chronic rhinosinusitis with nasal polyposis who are eligible to start biologicals as standard treatment.
- Trial name
- NASUMAB (NCT05938972)
- Testing
- Mepolizumab
- Where
- Belgium
- Volunteers
- 180 people
- Sponsor
- University Hospital, Ghent
Severe Asthma, Allergy to House Dust Mites
Potency of HDM Sublingual AIT Tablets in Assuring the Persistency of Asthma Control in HDM Allergic Patients With Severe Asthma, Treated With Tezepelumab
The aim of this drug trial is to evaluate the annualized asthma exacerbation rate under treatment with Acarizax versus placebo. The trial is intended for adults aged 18 to 65 with severe uncontrolled asthma and a house dust mite…
- Trial name
- TEZEPAIT (NCT07013123)
- Testing
- Tezepelumab, Acarizax
- Volunteers
- 38 people
- Sponsor
- University Hospital, Montpellier
Asthma
Safety Study of a Vitamin E Supplement in Normal Volunteers and Those With Both Allergy and Asthma
Gamma tocopherol (gt) is a naturally occurring form of vitamin E that is found in many foods, and is also commercially available as a vitamin supplement.
- Trial name
- NCT00386178
- Testing
- Vitamin E supplement rich in gamma tocopherol
- Where
- United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- University of North Carolina, Chapel Hill
Allergic Asthma
A Study to Evaluate the Safety and Efficacy of HAE1 in Subjects With Moderate to Severe Allergic Asthma
This is a Phase II, multicenter, randomized, double blind, placebo controlled, multiple-dose study designed to evaluate the efficacy, safety, and tolerability of subcutaneously administered HAE1 in subjects 12-75 years old with…
- Trial name
- NCT00406965
- Testing
- HAE1 (PRO98498)
- Volunteers
- 50 people
- Sponsor
- Genentech, Inc.
Asthma, Eosinophilic Asthma
Comparing Treatment Efficacy With Mepolizumab and Omalizumab in Severe Asthma - "Choosebetweenamab".
Mepolizumab is an anti-interleukin-5 ( IL-5) monoclonal antibody that neutralizes IL-5 and reduces eosinophil counts in both sputum and blood.
- Trial name
- NCT04585997
- Testing
- Mepolizumab, Omalizumab
- Where
- Australia
- Volunteers
- 200 people
- Sponsor
- University of Newcastle, Australia
Asthma Atopic, Asthma Severe Persistent Uncontrolled
Expression of TSLP Isoforms in Asthma
Asthma is a heterogeneous disease characterized by chronic airway inflammation, leading to variable airflow obstruction, bronchial hyperresponsiveness, excessive mucus secretion, and, consequently, structural airway remodeling.
- Trial name
- NCT07786870
- Testing
- No Intervention: Observational Cohort
- Where
- Poland
- Volunteers
- 70 people, healthy volunteers welcome
- Sponsor
- Medical University of Warsaw
Allergic Asthma
Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists
This study aims to investigate the effect of omalizumab on the number of tissue eosinophils and other markers of airway inflammation and remodeling, including thickness of the lamina reticularis, in moderate to severe asthmatics…
- Trial name
- eXplore (NCT00670930)
- Testing
- omalizumab at a dose of 0.016mg/kg/IU/mL
- Where
- 16 sites in United States, Canada and 5 more
- Volunteers
- 36 people
- Sponsor
- Novartis Pharmaceuticals
Allergic Asthma, Severe Eosinophilic Asthma
Non-coding RNAs Analysis of Eosinophil Subtypes in Asthma
Chronic airway inflammation rich in eosinophils is an important feature seen in asthma. Airway and blood eosinophilia is associated with increased rates of asthma exacerbations and more intense treatment.
- Trial name
- NCT04542902
- Testing
- Dermatophagoides pteronyssinus allergen, Blood sampling, Bronchial challenge with allergen
- Where
- Lithuania
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Lithuanian University of Health Sciences
Allergic Asthma, Uncontrolled Moderate to Severe
Efficacy and Safety of Zerafil® (Omalizumab) in Participants With Uncontrolled Moderate to Severe Allergic Asthma
The purpose of this study is to evaluate the efficacy and safety of Omalizumab produced by CinnaGen compared with Xolair® (Genentech, Inc., USA And Novartis Pharmaceuticals Corp, Switzerland) in subjects with uncontrolled…
- Trial name
- NCT05813470
- Testing
- Omalizumab (CinnaGen), Omalizumab (Genentech, Inc., USA and Novartis Pharmaceuticals Corp, Switzerland)
- Where
- 22 sites in Iran
- Volunteers
- 256 people
- Sponsor
- Cinnagen
Asthma
Repeat Dose Study of GSK3772847 in Participants With Moderate to Severe Asthma With Allergic Fungal Airway Disease (AFAD)
This study is multicenter, double-blinded parallel group design, where participants with moderate to severe asthma with AFAD will be enrolled.
- Trial name
- NCT03393806
- Testing
- GSK3772847
- Where
- 18 sites in France, Netherlands and 2 more
- Volunteers
- 17 people
- Sponsor
- GlaxoSmithKline
Asthma
Effect of Omalizumab in Patients With Severe Persistent Non-atopic Uncontrolled Asthma
This study will assess the change in the expression of FcεRI receptors of blood basophils and dendritic cells after 16 weeks of treatment with omalizumab as compared with placebo, in adult patients with non-atopic severe…
- Trial name
- NATAIR (NCT01007149)
- Testing
- omalizumab
- Where
- 10 sites in France
- Volunteers
- 79 people
- Sponsor
- Novartis Pharmaceuticals
Moderate to Severe Allergic Asthma
A Clinical Study of Omalizumab in the Treatment of Allergic Asthma(ESSENCE)
Allergic asthma being the most widespread and easily identifiable phenotype, accounting for 60-80% of cases.Previous studies have reported that nearly 90% of patients with severe asthma were cases of allergic asthma, in which…
- Trial name
- ESSENCE (NCT06348407)
- Testing
- IgE monoclonal antibody
- Where
- China
- Volunteers
- 300 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Asthma
Safety and Tolerability of Omalizumab in Adults and Adolescents With Severe Allergic Asthma
This study will assess further the safety and tolerability of long-term treatment with omalizumab by extending omalizumab treatment by 1 year for those patients with allergic asthma who successfully completed study CIGE25011E2.
- Trial name
- NCT00482248
- Testing
- Omalizumab
- Volunteers
- 132 people
- Sponsor
- Novartis
Moderate-to-severe Allergic Asthma
A Study to Assess the Impact of Omalizumab on Exercise Capacity, Physical Activity, and Sleep Quality in Participants With Moderate to Severe Allergic Asthma
This study will assess the effect of omalizumab on exercise capacity, physical activity, and sleep quality after 24 weeks of treatment in participants with moderate to severe allergic asthma.
- Trial name
- EDURO (NCT04195958)
- Testing
- Omalizumab
- Where
- 12 sites in United States
- Volunteers
- 3 people
- Sponsor
- Genentech, Inc.